Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb UFT

Executive Summary

FDA ad division objects to Bristol's dissemination of safety and efficacy data for UFT (uracil and tegafur) at ASCO in July 20 letter. "It is particularly concerning that BMS promoted this investigational drug as safe or effective in light of the fact that they received a 'not approvable' letter from the FDA in March of this year," the agency said (1"The Pink Sheet" April 2, In Brief). The ad division has issued at least nine letters regarding promotions at the May ASCO meeting (2"The Pink Sheet" July 30, p. 11)
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS038285

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel